drugset / Trial / NCT00062647

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

NCT00062647

Phase 2 Completed 60 enrolled Cumberland Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

Timeline

Start
2003-08
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Telavancin Other / unclassified 10 mg/kg Intravenous
Comparator Vancomycin Other / unclassified 1 g Intravenous
Comparator cloxacillin Other / unclassified 2 g Intravenous
Comparator nafcillin Small molecule 2 g Intravenous
Comparator oxacillin Small molecule 2 g Intravenous